Study Evaluating the Safety and Tolerability of NSA-789

Ascending Single Dose Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of NSA-789 Administered Orally to Healthy Subjects

This is the first time that NSA-789, a new compound being developed for schizophrenia, will be given to humans. Each healthy subject will receive a single dose, except for 8 subjects who will receive 2 doses-- one dose under fasting conditions and one dose after eating food.

Inclusion:

• Healthy men and women between 18 and 50 years old.
• Women must be of non-child-bearing potential (not able to have children).
• Must be of normal body weight.